General: All reagents were bought from Sigma Aldrich, Munich, Germany, unless otherwise noted, and were used without further purification. Thin‐layer chromatography was performed using Merck Silica Gel 60 F254 plates. For column chromatography, Silica Gel 60 (particle size 0.040–0.063 mm) (Sigma Aldrich, Munich, Germany) was used. Nuclear magnetic resonance (NMR) spectra were recorded with a Bruker AV‐400 NMR instrument (Bruker, Karlsruhe, Germany) in CDCl3 or [D6]DMSO. Chemical shifts are expressed in ppm relative to CDCl3 (7.26 ppm for 1H and 77.16 ppm for 13C) or [D6]DMSO (2.50 ppm for 1H and 39.52 ppm for 13C). The purity of the synthetic products was determined by HPLC (Shimadzu, Duisburg, Germany), containing a DGU‐20A3R degassing unit, an LC‐20AB liquid chromatograph, and an SPD‐20A UV/Vis detector. UV detection was done at 254 nm. Mass spectra were obtained by an LCMS‐2020 device (Shimadzu, Duisburg, Germany). As a stationary phase, a Synergi 4U fusion‐RP column (150 mm x 4.6 mm) was used, and, as a mobile phase, a gradient of methanol/water with 0.1 % formic acid. Parameters: A=water, B=methanol, V(B)/[(V(A)+ V(B)]=from 5 % to 90 % over 10 min, V(B)/[(V(A)+V(B)]=90 % for 5 min, V(B)/[(V(A)+V(B)]=from 90 % to 5 % over 3 min. The method was performed with a flow rate of 1.0 mL min−1. Compounds were used for biological evaluation only if the purity was 95 % or higher.
For the preparation of acetophenone 7 and aldehyde 8, see the Supporting Information.
Chalcone 9: A mixture of acetophenone 7 (650 mg, 2.16 mmol) in EtOH (10 mL) and a saturated solution of KOH in EtOH (15 mL) was stirred at 4 °C for 15 min. A solution of 8 (490 mg, 2.16 mmol) in EtOH (5 mL) was added dropwise and the mixture was allowed to stir overnight (16 h) at room temperature. The reaction was quenched with water and extracted with ethyl acetate. The combined organic layers were dried over Na2SO4 and the solvent was removed under reduced pressure. The crude product was purified by silica gel chromatography using a mixture of cyclohexane and ethyl acetate (3/1). The product was obtained as a yellow solid in 85 % yield (1.11 g). The analytical data were consistent with those reported in the literature.311H NMR (400 MHz, CDCl3): δ 7.35 (s, 1 H, Ar‐H), 7.26 (d, 2J=16.0 Hz, 1 H, HC=CH), 7.13 (s, 2 H, Ar‐H), 6.86 (d, 2J=16.0 Hz, 1 H, HC=CH), 6.43 (s, 2 H, Ar‐H), 5.25 (s, 2 H, CH2OCH3), 5.22 (s, 2 H, CH2OCH3), 5.11 (s, 4 H, CH2OCH3), 3.82 (s, 3 H, OCH3), 3.51 (s, 3 H, CH2OCH3), 3.50 (s, 3 H, CH2OCH3), 3.39 ppm (s, 6 H, CH2OCH3); 13C NMR (100 MHz, CDCl3): δ 194.4 (Cq, C=O), 162.1 (Cq, Ar‐C), 156.0 (2x Cq, Ar‐C), 149.4 (Cq, Ar‐C), 147.5 (Cq, Ar‐C), 144.7 (+, HC=CH), 129.4 (Cq, Ar‐C), 128.1 (+, HC=CH), 123.8 (+, Ar‐C), 116.3 (+, Ar‐C), 116.0 (+, Ar‐C), 113.8 (Cq, Ar‐C), 95.6 (−, CH2OCH3), 95.2 (−, CH2OCH3), 95.1 (2× +, Ar‐C), 94.6 (2x, −, CH2OCH3), 56.5 (+, CH2OCH3), 56.4 (+, CH2OCH3), 56.3 (2© +, CH2OCH3), 55.6 ppm (+, OCH3); ESI‐MS: m/z calcd for C24H30O10+H+: 479.19; found 479.2.
Sterubin (1): A solution of chalcone 9 (1.10 g, 2.32 mmol) in 10 % methanolic HCl was stirred for 30 min at 50 °C. NaOAc (3.80 g, 46.4 mmol) was added and the mixture was heated to reflux for 3 h, cooled, then water was added and the mixture was extracted with ethyl acetate. The combined organic layers were dried over Na2SO4 and the solvent was removed under reduced pressure. The crude product was purified by silica gel column chromatography using a mixture of dichloromethane and methanol (40/1) as the eluent. The product was obtained as a white solid in 55 % yield (391 mg). The analytical data were consistent with those reported in the literature.13a1H NMR (400 MHz, [D6]DMSO): δ 12.11 (s, 1 H, OH), 9.03 (m, 2 H, OH), 6.91–6.86 (m, 1 H, Ar‐H), 6.78–6.71 (m, 2 H, Ar‐H), 6.10 6.06 (m, 2 H, Ar‐H), 5.42 (dd, 3J=12.6, 3.0 Hz, 1 H), 3.79 (s, 3 H, OCH3), 3.24 (dd, 2J=17.2, 3J=12.6 Hz, 1 H), 2.72 (dd, 2J=17.2, 3J=3.1 Hz, 1 H); 13C NMR (100 MHz, [D6]DMSO): δ 196.9 (Cq, C=O), 167.4 (Cq, Ar‐C), 163.1 (Cq, Ar‐C), 162.8 (Cq, Ar‐C), 145.7 (Cq, Ar‐C), 145.1 (Cq, Ar‐C), 129.2 (Cq, Ar‐C), 117.9 (+, Ar‐C), 115.3 (+, Ar‐C), 114.3 (+, Ar‐C), 102.6 (Cq, Ar‐C), 94.5 (+, Ar‐C), 93.7 (+, Ar‐C), 78.6 (+, Ar‐C), 55.8 (+, CH3, OCH3), 42.1 (−, CH2). ESI‐MS: m/z calcd for C16H15O6+H+: 303.09; found 303.15.
For the preparation of 11, see the Supporting Information.
Tri‐O‐acetyldehydrosterubin: To a solution of tri‐O‐acetylsterubin (11) (160 mg, 0.374 mmol) and NBS (67 mg, 0.374 mmol) in chloroform (5 mL) benzoyl peroxide (6 mg, 26 μmol) was added and the reaction mixture was heated to reflux for 2 h. Further chloroform was added, and the mixture was washed with water and brine. The organic layer was dried over Na2SO4 and the solvent was removed under reduced pressure. The crude product was purified by silica gel chromatography using an eluent of cyclohexane and ethyl acetate (2:1 → pure ethyl acetate) and the product was obtained as a white solid in 63 % yield (100 mg). 1H NMR: (400 MHz, CDCl3): δ 7.73 (dd, 3J=8.5, 4J=2.2 Hz, 1 H, Ar‐H), 7.70 (d, 4J=2.1 Hz, 1 H, Ar‐H), 7.35 (d, 3J=8.5 Hz, 1 H, Ar‐H), 6.87 (d, 4J=2.5 Hz, 1 H, Ar‐H), 6.62 (d, 4J=2.4 Hz, 1 H, Ar‐H), 6.55 (s, 1 H, C=CH), 3.92 (s, 3 H, OCH3), 2.44 (s, 3 H, CH3COO), 2.35 (s, 3 H, CH3COO), 2.33 (s, 3 H, CH3COO); 13C NMR (100 MHz, CDCl3): δ 176.3 (Cq, C=O), 169.7 (Cq, CH3COO), 168.1 (Cq, CH3COO), 167.9 (Cq, CH3COO), 163.7 (Cq, Ar‐C), 160.3 (Cq, C=CH), 158.9 (Cq, Ar‐C), 150.7 (Cq, Ar‐C), 144.7 (Cq, Ar‐C), 142.7 (Cq, Ar‐C), 130.2 (Cq, Ar‐C), 124.5 (+, Ar‐C), 124.3 (+, Ar‐C), 121.6 (+, Ar‐C), 111.3 (Cq, Ar‐C), 109.0 (+, C=CH), 108.6 (+, Ar‐C), 99.2 (+, Ar‐C), 56.1 (+, OCH3), 21.2 (CH3COO), 20.8 (CH3COO), 20.7 (CH3COO); ESI‐MS: m/z calcd for C22H18O9+H+: 427.10; found 427.20.
Dehydrosterubin (12): A solution of tri‐O‐acetyldehydrosterubin (97 mg, 0.227 mmol) in acetonitrile (3 mL) and conc. aqueous HCl (3 mL) was heated to reflux for 1.5 h. Yellow precipitant was formed, which was filtered off, washed with water, and dried under vacuum. The product was obtained as a yellow solid in 50 % yield (34 mg). 1H NMR (400 MHz, [D6]DMSO): δ 12.97 (s, 1 H, OH), 9.96 (s, 1 H, OH), 9.37 (s, 1 H, OH), 7.44 (m, 2 H, Ar‐H), 6.90 (d, 3J=8.1 Hz, 1 H, Ar‐H), 6.72 (s, 1 H, C=CH), 6.71 (d, 4J=2.5 Hz, 1 H, Ar‐H), 6.37 (d, 4J=2.2 Hz, 1 H, Ar‐H), 3.87 (s, 3 H, OCH3); 13C NMR (100 MHz, [D6]DMSO): δ 181.7 (Cq, C=O), 165.0 (Cq, Ar‐C), 164.2 (Cq, Ar‐C), 161.1 (Cq, C=CH), 157.1 (Cq, Ar‐C), 149.8 (Cq, Ar‐C), 145.7 (Cq, Ar‐C), 121.3 (Cq, Ar‐C), 119.0 (+, Ar‐C), 115.9 (+, Ar‐C), 113.5 (+, Ar‐C), 104.6 (Cq, Ar‐C), 103.0 (+, C=CH), 97.9 (+, Ar‐C), 92.5 (+, Ar‐C), 56.0 (+, OCH3); ESI‐MS: m/z calcd for C16H12O6+H+: 301.07; found 301.15.
Plant material: Leaves of Eriodictyon californicum Hook. & Arn. (Boraginaceae) were collected by Ms. Kyra Bobine in May, 2019.
Plant extraction: Dried leaves of E. californicum (18.6 g) were soaked in ethyl acetate (3×100 mL), ultrasonicated for 30 min, then shaken overnight (≈16 h) at room temperature. The crude extract was filtered, and the filtrate was concentrated in vacuo. The obtained residue (2.0 g) was re‐dissolved in 90 % aqueous methanol. By addition of n‐hexane, chlorophyll and non‐polar residues were removed and sterubin (1) and related flavones were precipitated. After filtration, the precipitate (0.6 g) was dissolved in methanol and directly subjected to HPLC on a ChiralPak‐IA column.
Chiral resolution of racemic sterubin: An HPLC‐UV guided resolution of the enantiomers of 1 was performed on a Jasco system equipped with a DG‐2080 degassing unit, a PU‐1580 ternary pump, an MD‐2010 plus multiwavelength detector, and an AS‐2055 autosampler. Separation of the enantiomers was done on a ChiralPak IA® (10×25 mm, 5 μm, Daicel Chemical Industries) column using a gradient system with initial conditions 32 % B (B: 90 % MeCN in water + 0.05 % TFA) to 60 % B in 29 min. The (R)‐ and (S)‐enantiomers of sterubin, (R)‐1 and (S)‐1, had retention times of 17.8 min and 20.2 min, respectively.
Online LC‐ECD analysis of the sterubin enantiomers: ECD spectroscopic analysis was performed using a Jasco J‐715 spectropolarimeter. Measurements were done at room temperature and the spectra were processed using the SpecDis software.32Oxytosis assay: HT22 cells were grown in Dulbecco's Modified Eagle Medium (DMEM, Sigma Aldrich, Munich, Germany) supplemented with 10 % (v/v) fetal calf serum (FCS) and 1 % (v/v) penicillin‐streptomycin. 5×103 HT22 cells per well were seeded into sterile 96‐well plates and incubated overnight (≈16 h). Aqueous glutamate solution (5 mm) (monosodium‐l‐glutamate, Sigma Aldrich, Munich, Germany) together with 2.5, 5.0, 7.5, or 10 μm of the respective compound was added to the cells and incubated for 24 h. Quercetin (25 μm) (Sigma Aldrich, Munich, Germany) together with glutamate (5 mm) served as a positive control. After 24 h incubation cell viability was determined using a colorimetric 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT, Sigma Aldrich, Munich, Germany) assay. MTT solution (5 mg mL−1 in PBS) was diluted 1:10 with medium and added to the wells after removal of the old medium. Cells were incubated for 3 h and then lysis buffer (10 % SDS) was added. The next day, absorbance at 560 nm was determined with a multiwell plate photometer (Tecan, SpectraMax 250). Results are presented as percentage of untreated control cells. All data are expressed as means ± SEM of three independent experiments. Analysis was accomplished using GraphPad Prism 5 Software applying Oneway ANOVA followed by Dunnett's multiple comparison posttest. Levels of significance: * p<0.05; ** p<0.01; *** p<0.001.
Cellular uptake and racemization experiments: 2×106 BV2 cells were grown in sterile 100 mm dishes overnight and 4 mL 50 μm (S)‐1 or (R)‐1 diluted in cell culture medium were added. Cells were incubated for the indicated time periods, after which the supernatant was removed, and cells were washed twice with PBS. Further PBS (1 mL) was added, cells were scraped and transferred to Eppendorf tubes. The samples were centrifuged and resuspended in 200 μL of MeOH. The cells were frozen in liquid nitrogen and thawed at 37 °C (10 times). Cell debris was pelleted by centrifugation and the supernatant was collected for HPLC analysis.
Neuroprotection studies in vivo: The in vivo behavioral experiments were performed as established and published previously.15, 33 Neurotoxicity was induced by ICV injection of oligomerized Aβ25–35 peptide, and sterubin (1) was evaluated for its neuroprotective properties. Sterubin was dissolved in 60 % DMSO and 40 % saline (0.9 % NaCl in milliQ water) and was injected once per day IP on days 1–7 to give doses of 0.3, 1, and 3 mg kg−1. The oligomerized Aβ25–35 peptide was injected ICV on day 1 of the study. The behavior of the mice was evaluated on day 8 (YMT) and days 9 and 10 (STPA). On day 11, the mice were sacrificed, and the brains were collected. Samples were frozen at −80 °C for further biochemical analysis.
Animals: Male Swiss mice 6 weeks old, body weight 30–40 g, obtained from JANVIER (Saint Berthevin, France) were housed in the animal facility of the University of Montpellier (CECEMA, Office of Veterinary Services agreement #B‐34‐172‐23) with access to food and water ad libitum (except during behavioral tests). The humidity and temperature were controlled, and the mice were kept at a 12 h light/12 h dark cycle (lights off at 7:00 p.m.). All animal procedures were conducted in strict adherence to the European Union directives of September 22nd, 2010 (2010/63/UE) and to the ARRIVE guidelines. The project was authorized by the French National Ethics Committee (APAFIS #1485‐15 034). Animals were assigned to different treatment groups randomly.
Preparation of sterubin injections: Sterubin (1) was dissolved in 100 % DMSO at a concentration of 6 mg mL−1 to give a stock solution, which was diluted with saline (0.9 % NaCl in milliQ water) and DMSO to the final test concentration and a final percentage of 60 % DMSO. 60 % DMSO in saline served as the vehicle (V2). After compound injections, the behavior of the mice in their home cage was checked visually. Weight was examined once per day. As demonstrated in Figure S1, a tendency was observed that weight gain was facilitated with an increasing dose of 1. Nevertheless, the difference in weight gain remained insignificant compared to Aβ+V2 treated mice in Dunnett's multiple comparison test.
Amyloid peptide preparation and ICV injection: All experiments followed previously described protocols.15, 25, 32 The Aβ25–35 peptide was prepared according to Maurice et al.15 Mice were anesthetized with 2.5 % isoflurane. Then, oligomerized Aβ25–35 peptide (9 nmol in 3 μL/mouse) was injected ICV. Bidistilled water was used as a vehicle (V1).
Spontaneous alternation performance in a Y‐maze: On day 8 of the study, the spatial working memory of all mice was evaluated in the Y‐maze.15, 25, 32 The Y‐maze is made from grey polyvinylchloride and has three identical arms (length 40 cm, height 13 cm, bottom width 3 cm, top width 10 cm (walls converge at an equal angle). For evaluation of memory, every mouse was placed into one arm and was allowed to explore the maze for 8 min. All entries into an arm (including the return into the same arm) were counted and the number of alternations (mouse entered all three arms consecutively) was calculated as percentage of total number of arm entries [alternations/ (arm entries−2)×100].
Step‐through passive avoidance test: STPA was performed on day 9 and day 10 in a two‐compartment box [(width 10 cm, total length 20 cm (10 cm per compartment), height 20 cm] consisting of polyvinylchloride. One of the compartments was white and illuminated with a bulb (60 W, 40 cm above the center of the compartment), the second compartment was black, covered, and had a grid floor. A guillotine door separated the compartments. On day 9 (training), each animal was placed in the white compartment and was left to explore for 5 s. Then, the door was opened, which allowed the mouse to enter the black compartment. After it had entered, the door was closed, and a foot shock was delivered (0.3 mA) for 3 s generated by a scramble shock generator (Lafayette Instruments, Lafayette, USA). The step‐through latency (time the mouse spent in the white compartment after the door was opened) and the level of sensitivity (no sign=0, flinching reactions=1, vocalization=2) were recoded. Treatment with sterubin (1) did not affect the measured parameters. On the next day (day 10), each mouse was placed in the white compartment and was allowed to explore for 5 s. Then, the door was opened allowing the mouse to step over into the black compartment. The step‐through latency was measured for up to 300 s.
Sacrifice and brain collection: All animals were sacrificed on day 11. The brains were collected, hippocampus and cortex were isolated, and the samples were frozen at −80 °C.
Statistical analysis: Weight gain and results from the YMT were analyzed by the software GraphPad Prism 5.0 using one‐way ANOVA, followed by Dunnett's post‐hoc multiple comparison test. STPA had a maximum step‐through latency of 300 s. Therefore, a Gaussian distribution could not be assumed. The results were analyzed using a Kruskal‐Wallis non‐parametric ANOVA, followed by a Dunn's multiple comparison test. p<0.05 was considered significant.
Novel‐object recognition test: Male C57Bl/6J mice were used and the testing was done by Scripps Research. All mice were acclimated to the colony room for at least 2 weeks prior to testing and were tested at an average age of 8 weeks. Mice were randomly assigned across treatment groups with 11 mice in each group. For each dose tested, a solution of sterubin in corn oil was prepared. The vehicle was corn oil alone. All were administered orally 60 min prior to the training session at a volume of 10 mL kg−1 body weight. Rolipram was dissolved in 10 % DMSO and administered intraperitoneally at 0.1 mg kg−1 20 min prior to training. The test was performed as described previously.29 Briefly, on day 1 mice were habituated to a circular open field arena for one hour in cage groups of four. 24 h later, individual mice were placed back in the same arena which now contained two identical objects for a 15 min training trial. On day 3, vehicle‐, sterubin‐ or rolipram‐treated mice were individually placed back in the same arena in the presence of both the familiar object (i.e., previously explored) and a novel object. The spatial positions of the objects were counter‐balanced between subjects. Each animal's test trial was recorded and the first 10 min of each session were scored. Object recognition was computed using the formula: Time spent with novel object x 100)/Total time spent exploring both objects. Data were analyzed by a one‐way ANOVA followed by post‐hoc comparisons with Fisher's test.
Hofmann J., Fayez S., Scheiner M., Hoffmann M., Oerter S., Appelt‐Menzel A., Maher P., Maurice T., Bringmann G, & Decker M. (2020). Sterubin: Enantioresolution and Configurational Stability, Enantiomeric Purity in Nature, and Neuroprotective Activity in Vitro and in Vivo. Chemistry (Weinheim an Der Bergstrasse, Germany), 26(32), 7299-7308.